Tag: cathepsin K inhibitor

1. In this double-blind phase 2a trial, cathepsin K inhibitor MIV-711 did not show a significant benefit in reducing pain but proved effective in delaying structural changes associated with progression of osteoarthritis. 2. Biomarkers of bone resorption were significantly reduced in both treatment groups but returned to baseline levels after...
1. In this double-blind phase 2a trial, cathepsin K inhibitor MIV-711 did not show a significant benefit in reducing pain but proved effective in delaying structural changes associated with progression of osteoarthritis. 2. Biomarkers of bone resorption were significantly reduced in both treatment groups but returned to baseline levels after...
Odanacatib for the Treatment of Postmenopausal Osteoporosis: Results of the LOFT Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial and LOFT Extension Study 1. The cathepsin K inhibitor odanacatib reduced the risk of fracture but was associated with significantly increased risk of cardiovascular events, specifically stroke, in postmenopausal women with osteoporosis compared to...